Obesity, essential hypertension and renin-angiotensin system (Q34695154)

4 August 2017

1 reference

title

Obesity, essential hypertension and renin-angiotensin system (English)

1 reference

4 August 2017

0 references

essential hypertension

1 reference

Julian Segura

1

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 October 2007

1 reference

4 August 2017

published in

Public Health Nutrition

1 reference

4 August 2017

volume

10

1 reference

4 August 2017

issue

10A

1 reference

4 August 2017

page(s)

1151-1155

1 reference

The metabolic syndrome and chronic kidney disease in U.S. adults

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Choice of drug treatment for obesity-related hypertension: where is the evidence?

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Trends and correlates of class 3 obesity in the United States from 1990 through 2000.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Lifetime Health and Economic Consequences of Obesity

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Is there a rationale for angiotensin blockade in the management of obesity hypertension?

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

The kidney, hypertension, and obesity

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Epidemic Obesity and the Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Epidemiology of the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Role of adipose tissue for cardiovascular-renal regulation in health and disease

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Angiotensinogen, angiotensin II and adipose tissue development

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Metabolic syndrome and target organ damage in untreated essential hypertensives.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Differential Effects of LocalVersusSystemic Angiotensin II in the Regulation of Leptin Release from Adipocytes

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Weight loss and the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Obesity-associated hypertension: new insights into mechanisms.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Blood pressure control and physician management of hypertension in hospital hypertension units in Spain

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Human adipocytes secrete mineralocorticoid-releasing factors

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Metabolic syndrome and age-related progression of aortic stiffness

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Epidemia de enfermedades metabólicas. Una llamada de atención

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study.

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Do we need to target 'prediabetic' hypertensive patients?

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

Antihypertensive therapy in patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1017%2FS136898000700064X

7 January 2021

10.1017/S136898000700064X

Identifiers

DOI

1 reference

4 August 2017

1 reference